Authors
Loading...
Analysis shows 43% rise in FDA warning letters between 2019-2023, highlighting evolving regulatory priorities.
Kwiecinski et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: